Last week, the U.S. Centers for Disease Control and Prevention, and the Food and Drug Administration, announced that vaccine providers may once again distribute the Johnson & Johnson vaccine after reports of blood clotting in a handful of recipients.
As a result, New York has resumed using the one-shot Johnson & Johnson vaccine.
“The state of New York will resume administration of this vaccine at all of our state-run sites effective immediately. The vaccine is the weapon that will win the war against COVID and allow everyone to resume normalcy, and we have three proven vaccines at our disposal. I urge every New Yorker to take whichever one is available to them first. The sooner we all get vaccinated, the sooner we can put the long COVID nightmare behind us once and for all.” said Gov. Andrew Cuomo.
The European Medicines Agency said a few serious cases of clotting and low platelets occurred in the U.S. during the rollout of Johnson & Johnson’s vaccine According to the Centers for Disease Control and Prevention, the CDC, this was found evident in adult women younger than 50 years old.
The Food and Drug Administration said it was aware of the blood clot issue and also had not found “a causal relationship with vaccination,” the company said in a statement to Reuters.
Up to this point, 29 percent of the U.S. population has been fully vaccinated while 43 percent has received their first vaccination.
“The data has shown the vaccine’s known benefits far outweigh the potential and extremely rare risks, but we urge anyone with questions about the COVID-19 vaccines to speak with their healthcare provider. We will continue to communicate regular updates and guidance from the federal government to providers and the general public about the Johnson & Johnson vaccine and all vaccines on the market,” said State Health Commissioner Dr. Howard Zucker.
